Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tadalafil for Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulant males with Duchenne muscular dystrophy (DMD) confirmed by typical clinical presentation (onset of clinical signs or symptoms before 6 years of age supported by an elevated serum creatinine kinase level, and ongoing difficulty with walking) together with either a record of a genetic confirmation of the DMD diagnosis, or a record of muscle biopsy showing near-complete dystrophin deficiency (excluding revertant fibers)~* Receiving systemic corticosteroids for a minimum of 6 months immediately prior to screening, with no significant change in total daily dosage or dosing regimen (except those adjusting for weight changes) for a minimum of 3 months immediately prior to screening and a reasonable expectation that total daily dosage and dosing regimen will not change significantly (except for adjustments for weight) for the duration of the study~* Able to complete the six minute walk distance (6MWD) test with results within 20% of each other at a minimum of 2 pre-randomization assessments~* Left ventricular ejection fraction (LVEF) ≥50% as determined by echocardiogram~* Written informed consent from parents/legal guardian will be obtained prior to any study procedure being performed. In addition, the child may be required to give documented assent, if capable.~Exclusion Criteria:~* Symptomatic cardiomyopathy or heart failure~* Change in prophylactic treatment for heart failure within 3 months prior to start of study treatment~* Cardiac rhythm disorder~* History of participation in gene or cell-based therapy , or antisense oligonucleotide or stop codon read-through therapy~* Unable to take orally administered tablets~* Use of any pharmacologic treatment, other than corticosteroids, that might have an effect on muscle strength within 3 months prior to the start of study treatment (for example, growth hormone, anabolic steroids including testosterone)~* New or changed treatment with herbal or dietary supplements being taken with an expectation of an effect on muscle strength or function during 1 month prior to first dose of study drug~* Surgery that might have an effect on muscle strength or function within 3 months before study entry or planned surgery at any time during the study~* Evidence of a lower limb injury that may affect performance on the 6MWD~* Severe behavioral problems, including severe autism or attention deficit disorders, that may interfere with completion of the 6MWD~* Any contraindication to tadalafil (use of any form of organic nitrate, either regularly and/or intermittently, or known serious hypersensitivity to tadalafil)~* History of significant renal insufficiency or clinical evidence of cirrhosis~* Have known allergy to any of the excipients in tadalafil tablets, notably lactose~* Current Phosphodiesterase Type 5 (PDE5) inhibitor therapy or treatment within the past 6 months

- Gender: MALE
- Minimum Age: 7 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: EXPERIMENTAL): Placebo taken orally once daily.
- 0.3 mg/kg Tadalafil (Type: EXPERIMENTAL): 0.3 milligram per kilogram (mg/kg) tadalafil taken orally once daily.
- 0.6 mg/kg Tadalafil (Type: EXPERIMENTAL): 0.6 mg/kg tadalafil taken orally once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).